This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...
RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback